$ATNM
Actinium Pharmaceuticals, Inc.

2024 Q3 Form 10-Q Financial Statement

#000121390024065239 Filed on August 05, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2023 Q4
Revenue $81.00K
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.827M $3.593M $2.306M
YoY Change 3.59% -21.22% -41.74%
% of Gross Profit
Research & Development $9.774M $8.825M $8.118M
YoY Change -15.9% -20.36% 10.71%
% of Gross Profit
Depreciation & Amortization $202.0K $189.0K $199.0K
YoY Change 1.0% -9.57% 23.6%
% of Gross Profit
Operating Expenses $12.60M $12.42M $10.42M
YoY Change -12.19% -20.61% -7.68%
Operating Profit -$12.60M -$12.42M
YoY Change -12.19% -20.61%
Interest Expense $1.033M $1.065M $1.019M
YoY Change -3.91% 131.02% 58.23%
% of Operating Profit
Other Income/Expense, Net $1.033M $1.065M
YoY Change -3.91% 131.02%
Pretax Income -$11.57M -$11.35M -$9.324M
YoY Change -12.87% -25.22% -12.43%
Income Tax
% Of Pretax Income
Net Earnings -$11.57M -$11.35M -$9.324M
YoY Change -12.87% -25.22% -12.43%
Net Earnings / Revenue -11511.11%
Basic Earnings Per Share -$0.37 -$0.38
Diluted Earnings Per Share -$0.37 -$0.38 -$0.34
COMMON SHARES
Basic Shares Outstanding 31.15M shares 29.78M shares 27.41M shares
Diluted Shares Outstanding 31.07M shares 30.10M shares

Balance Sheet

Concept 2024 Q3 2024 Q2 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $78.66M $86.04M $76.68M
YoY Change -5.2% -5.74% -29.6%
Cash & Equivalents $78.66M $86.04M $76.68M
Short-Term Investments
Other Short-Term Assets $860.0K $1.031M $1.586M
YoY Change -67.15% -75.8% -21.95%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $79.52M $87.07M $78.26M
YoY Change -7.1% -8.86% -29.46%
LONG-TERM ASSETS
Property, Plant & Equipment $412.0K $460.0K $2.869M
YoY Change -31.45% -26.28% 375.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $322.0K $318.0K $313.0K
YoY Change 3.87% 3.58% 3.64%
Total Long-Term Assets $2.594M $2.793M $3.182M
YoY Change -22.52% -20.52% -2.09%
TOTAL ASSETS
Total Short-Term Assets $79.52M $87.07M $78.26M
Total Long-Term Assets $2.594M $2.793M $3.182M
Total Assets $82.11M $89.86M $81.45M
YoY Change -7.68% -9.28% -28.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.195M $9.177M $7.953M
YoY Change -11.72% 6.25% -21.49%
Accrued Expenses $549.0K $540.0K $530.0K
YoY Change 5.37% 5.47% 7.29%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $11.00K $11.00K $11.00K
YoY Change 1000.0% 450.0% 175.0%
Total Short-Term Liabilities $7.755M $9.728M $8.494M
YoY Change -10.57% 6.31% -20.08%
LONG-TERM LIABILITIES
Long-Term Debt $12.00K $14.00K $19.00K
YoY Change
Other Long-Term Liabilities $36.14M $36.28M $36.55M
YoY Change -1.5% -1.46% -1.43%
Total Long-Term Liabilities $36.15M $36.30M $36.57M
YoY Change -1.47% -1.43% -1.38%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.755M $9.728M $8.494M
Total Long-Term Liabilities $36.15M $36.30M $36.57M
Total Liabilities $43.91M $46.03M $45.07M
YoY Change -3.21% 0.11% -5.54%
SHAREHOLDERS EQUITY
Retained Earnings -$369.2M -$357.6M -$337.6M
YoY Change 12.46% 13.53% 16.91%
Common Stock $31.00K $31.00K $28.00K
YoY Change 14.81% 14.81% 7.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $38.21M $43.84M $36.38M
YoY Change
Total Liabilities & Shareholders Equity $82.11M $89.86M $81.45M
YoY Change -7.68% -9.28% -28.68%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2023 Q4
OPERATING ACTIVITIES
Net Income -$11.57M -$11.35M -$9.324M
YoY Change -12.87% -25.22% -12.43%
Depreciation, Depletion And Amortization $202.0K $189.0K $199.0K
YoY Change 1.0% -9.57% 23.6%
Cash From Operating Activities -$11.98M -$7.972M -$7.490M
YoY Change 7.64% -41.57% -3.7%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.602M 9.954M 1.192M
YoY Change 60.91% -0.94% -75.64%
NET CHANGE
Cash From Operating Activities -11.98M -7.972M -7.490M
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities 4.602M 9.954M 1.192M
Net Change In Cash -7.373M 1.982M -6.298M
YoY Change -11.12% -154.42% 117.1%
FREE CASH FLOW
Cash From Operating Activities -$11.98M -$7.972M -$7.490M
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow -$11.98M -$7.972M -$7.490M
YoY Change 7.35% -41.77% -3.9%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
usd
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25958706 shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36374
dei Entity Registrant Name
EntityRegistrantName
ACTINIUM PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
74-2963609
dei Entity Address Address Line1
EntityAddressAddressLine1
100 Park Ave., 23rd Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10017
dei City Area Code
CityAreaCode
(646)
dei Local Phone Number
LocalPhoneNumber
677-3870
dei Security12b Title
Security12bTitle
Common stock, par value $0.001
dei Trading Symbol
TradingSymbol
ATNM
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
31154376 shares
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
86037000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
76677000 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1031000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1586000 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
87068000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
78263000 usd
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
794000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
694000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
460000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
550000 usd
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
318000 usd
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
313000 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1990000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2289000 usd
CY2024Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
25000 usd
CY2023Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
30000 usd
CY2024Q2 us-gaap Assets
Assets
89861000 usd
CY2023Q4 us-gaap Assets
Assets
81445000 usd
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
9177000 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
7953000 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
540000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
530000 usd
CY2024Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
11000 usd
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
11000 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
9728000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8494000 usd
CY2024Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
35000000 usd
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
35000000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1284000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1553000 usd
CY2024Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
14000 usd
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
19000 usd
CY2024Q2 us-gaap Liabilities
Liabilities
46026000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
45066000 usd
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30550602 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30550602 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27634213 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27634213 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
31000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
28000 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
401410000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
373934000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-357606000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-337583000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
43835000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
36379000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
89861000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
81445000 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8825000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11081000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15460000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18930000 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3593000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4561000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6555000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8296000 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
12418000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
15642000 usd
us-gaap Operating Expenses
OperatingExpenses
22015000 usd
us-gaap Operating Expenses
OperatingExpenses
27226000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12418000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-15642000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-22015000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-27226000 usd
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1065000 usd
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
461000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
1992000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
1008000 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1065000 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
461000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1992000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1008000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-11353000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-15181000 usd
us-gaap Net Income Loss
NetIncomeLoss
-20023000 usd
us-gaap Net Income Loss
NetIncomeLoss
-26218000 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.58
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.01
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30103063 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26217910 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28994775 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25958706 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
36379000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1378000 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
14695000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
75000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-8670000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
43857000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1374000 usd
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9957000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-11353000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
43835000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
66481000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
993000 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
770000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-11037000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
57208000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1001000 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9788000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
261000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-15181000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
53077000 usd
us-gaap Net Income Loss
NetIncomeLoss
-20023000 usd
us-gaap Net Income Loss
NetIncomeLoss
-26218000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2752000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1994000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
405000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
391000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-555000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2625000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1224000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1493000 usd
atnm Increase Decrease In Operating Lease Rightofuse Assets
IncreaseDecreaseInOperatingLeaseRightofuseAssets
-527000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-259000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-242000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15346000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28720000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
123000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-123000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
5000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
2000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
24652000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10558000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
75000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
262000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
24722000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10818000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
9365000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-18025000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76990000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
109608000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86355000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
91583000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Use of Estimates </b>- The preparation of these unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the unaudited interim condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2024Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
86037000 usd
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
76677000 usd
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
318000 usd
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
313000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86355000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76990000 usd
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5734 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5193 shares
CY2012Q2 atnm Payment Of Milestone
PaymentOfMilestone
1000000 usd
CY2012Q2 atnm Royalty Payments Percentage
RoyaltyPaymentsPercentage
0.02 pure
us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
5 years 2 months
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2027-07-30
us-gaap Payments For Rent
PaymentsForRent
600000 usd
CY2024Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
173000 usd
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
183000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
346000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
345000 usd
CY2024Q2 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
3000 usd
CY2023Q2 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
1000 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
5000 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
2000 usd
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1000 usd
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1000 usd
CY2024Q2 us-gaap Lease Cost
LeaseCost
3000 usd
CY2023Q2 us-gaap Lease Cost
LeaseCost
1000 usd
us-gaap Lease Cost
LeaseCost
6000 usd
us-gaap Lease Cost
LeaseCost
3000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
306000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
300000 usd
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
5000 usd
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
2000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
5000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
2000 usd
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y1M6D
CY2024Q2 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P2Y6M
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.048 pure
CY2024Q2 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.062 pure
CY2022Q2 us-gaap Advance Royalties
AdvanceRoyalties
35000000 usd
CY2024Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
35000000 usd
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
35000000 usd
CY2023Q3 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
500000000 usd
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
25200000 usd
atnm Net Proceed From Issuance Of Common Stock
NetProceedFromIssuanceOfCommonStock
24700000 usd
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
10900000 usd
atnm Net Proceeds From Issuance Of Common Stock
NetProceedsFromIssuanceOfCommonStock
10600000 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5445 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.8
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M12D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
373000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.15
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
10 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.39
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
16 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.7
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5420 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.8
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M26D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
10461000 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2121 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.22
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y3M10D
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3169000 usd
CY2024Q2 us-gaap Sale Of Stock Consideration Received Per Transaction
SaleOfStockConsiderationReceivedPerTransaction
4500000 usd
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.58
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.01
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26217910 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28994775 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30103063 shares
atnm Increase Decrease In Operating Lease Rightofuse Assets
IncreaseDecreaseInOperatingLeaseRightofuseAssets
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
CY2024Q2 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
usd
CY2023Q2 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
usd
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001388320

Files In Submission

Name View Source Status
0001213900-24-065239-index-headers.html Edgar Link pending
0001213900-24-065239-index.html Edgar Link pending
0001213900-24-065239.txt Edgar Link pending
0001213900-24-065239-xbrl.zip Edgar Link pending
atnm-20240630.xsd Edgar Link pending
atnm-20240630_cal.xml Edgar Link unprocessable
atnm-20240630_def.xml Edgar Link unprocessable
atnm-20240630_lab.xml Edgar Link unprocessable
ea0209503-10q_actinium.htm Edgar Link pending
ea020950301ex31-1_actinium.htm Edgar Link pending
ea020950301ex31-2_actinium.htm Edgar Link pending
ea020950301ex32-1_actinium.htm Edgar Link pending
ea020950301ex32-2_actinium.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
atnm-20240630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ea0209503-10q_actinium_htm.xml Edgar Link completed